CBD Neuroprotection Research Must Separate Cell Survival From Slower Human Disease Progression

A 2022 review found the preclinical CBD evidence in neurodegenerative disease more convincing than the clinical evidence. Protective effects in laboratory models do not establish that CBD slows Parkinson's or Alzheimer's disease in people.

The review crossed several evidence levels

The authors considered cannabinoid targets, anti-inflammatory mechanisms and studies involving Parkinson's and Alzheimer's disease. These levels can inform one another, but a molecular mechanism, an animal outcome and a patient benefit are not equivalent demonstrations.

Symptom relief and disease modification differ

An improvement in a symptom can matter without showing that the underlying disease progresses more slowly. Establishing disease modification requires outcomes and follow-up suited to that claim. The review's discussion of neuroprotective potential does not supply that missing clinical result.

Clinical uncertainty remained explicit

The authors called for larger, well-designed randomized trials. Their conclusion does not identify a proven preventive dose or establish equivalence among cannabis, THC and purified CBD. Each intervention requires its own clinical evidence and safety assessment.

Interpreting the evidence

When neuroprotection is invoked, ask what was protected, in which system and over what interval. Then distinguish that result from patient function and disease trajectory. This review supports a research rationale, not an established treatment for preventing or reversing neurodegeneration.

Related reading: interpreting cannabis tolerance claims.

Research reference

Milena de Barros Viana; Pedro Everson Alexandre de Aquino; Débora Estadella; Daniel Araki Ribeiro; Glauce Socorro de Barros Viana (2022). Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases?. Medical Cannabis and Cannabinoids. doi:10.1159/000527335.

This analysis draws on the supplied review’s abstract and introductory material.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

An Isolated-Heart Study Linked Angiotensin Responses to Endocannabinoid Signaling Without Testing Marijuana

A 2021 rat-heart experiment found evidence that endogenous cannabinoid signaling modulated angiotensin II responses. The intervention and model did not establish the cardiovascular effects of using marijuana or taking THC. The preparation isolated a mechanistic question Researchers used perfused rat hearts and confirmed cardiac CB1 receptor expression. Angiotensin infusions changed…

Spread the love

Read Article: An Isolated-Heart Study Linked Angiotensin Responses to Endocannabinoid Signaling Without Testing Marijuana

An Isolated Intestinal Cannabinoid Study Found Two-Way Cross-Tolerance but Unequal Antagonist Withdrawal Responses

A 1999 isolated guinea-pig intestinal-tissue experiment found bidirectional cross-tolerance between morphine and WIN 55,212-2. Yet antagonist-triggered contraction did not appear symmetrically, limiting a simple claim that the two dependence states were identical. The model measured tissue responses Myenteric-plexus longitudinal-muscle preparations were incubated with the compounds and tested through electrically evoked…

Spread the love

Read Article: An Isolated Intestinal Cannabinoid Study Found Two-Way Cross-Tolerance but Unequal Antagonist Withdrawal Responses

A Mouse THC Withdrawal Model Used Receptor Blockade Rather Than Ordinary Abstinence

A 1998 mouse study used a CB1 antagonist to precipitate withdrawal after repeated THC. Its behavioral findings support an experimental dependence model, while remaining different from the natural course of human cannabis withdrawal. The trigger was an administered antagonist After repeated THC, antagonist challenge promptly increased paw tremors and head…

Spread the love

Read Article: A Mouse THC Withdrawal Model Used Receptor Blockade Rather Than Ordinary Abstinence

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us